PNC FINANCIAL SERVICES GROUP, INC. - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.

Quarter-by-quarter ownership
PNC FINANCIAL SERVICES GROUP, INC. ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$309,015
+109.7%
6,808
+159.4%
0.00%
Q2 2023$147,368
+28.9%
2,625
+3.8%
0.00%
Q1 2023$114,341
-0.5%
2,528
-10.6%
0.00%
Q4 2022$114,958
-40.7%
2,828
-4.3%
0.00%
Q3 2022$194,000
+12.8%
2,954
+4.5%
0.00%
Q2 2022$172,000
-9.0%
2,828
-6.2%
0.00%
Q1 2022$189,000
-80.3%
3,016
-76.2%
0.00%
-100.0%
Q4 2021$960,000
-35.0%
12,677
-3.9%
0.00%0.0%
Q3 2021$1,478,000
-29.6%
13,195
+1.7%
0.00%
-50.0%
Q2 2021$2,100,000
+28.2%
12,976
-3.5%
0.00%0.0%
Q1 2021$1,638,000
-15.1%
13,441
+6.6%
0.00%0.0%
Q4 2020$1,930,000
+100.8%
12,603
+9.6%
0.00%
+100.0%
Q3 2020$961,000
+20.4%
11,500
+5.9%
0.00%0.0%
Q2 2020$798,000
-10.1%
10,860
-48.2%
0.00%0.0%
Q1 2020$888,000
-29.1%
20,960
+1.9%
0.00%0.0%
Q4 2019$1,252,000
+46.4%
20,560
-1.4%
0.00%0.0%
Q3 2019$855,000
-16.2%
20,846
-3.7%
0.00%0.0%
Q2 2019$1,020,000
+31.8%
21,6460.0%0.00%0.0%
Q1 2019$774,000
+25.6%
21,646
+0.3%
0.00%0.0%
Q4 2018$616,000
+142.5%
21,586
+277.5%
0.00%
Q3 2018$254,000
-56.3%
5,718
-42.2%
0.00%
-100.0%
Q2 2018$581,0009,8940.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q1 2023
NameSharesValueWeighting ↓
Gilfoyle Management LLC 150$6,37612.96%
Versant Venture Management, LLC 498,558$22,629,54812.03%
NEA Management Company, LLC 1,587,854$72,072,6935.57%
ARK Investment Management 7,163,118$325,133,9132.49%
Nikko Asset Management Americas, Inc. 3,465,470$157,263,0291.88%
Integral Health Asset Management, LLC 275,000$12,482,2501.73%
Merlin Capital, Inc 9,092$412,6861.54%
Del-Sette Capital Management, LLC 33,977$1,542,2161.52%
Green Alpha Advisors, LLC 34,880$1,583,2031.22%
Ikarian Capital, LLC 2,039$9,255,0211.11%
View complete list of CRISPR THERAPEUTICS AG shareholders